OncoCyte Corp expected to post a loss of 43 cents a share - Earnings Preview

Insight Molecular Diagnostics

21/03/2025 23:02

OncoCyte Corp OCX.OQ OCX.O is expected to show a fall in quarterly revenue when it reports  results on March 24 for the period ending December 31 2024

The Irvine California-based  company is expected to report a 68.2% decrease in revenue to $100 thousand from $314 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for OncoCyte Corp is for a loss of 43 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for OncoCyte Corp is $4.13​, above​ its last closing price of $3.40. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.44
-0.44
-0.98
Missed
-124.8
Jun. 30 2024
-0.55
-0.56
-0.36
Beat
35.6
Mar. 31 2024
-0.65
-0.67
-1.13
Missed
-69.1​
Dec. 31 2023
-1.14
-2.12
Missed
-86.5
​​Sep. 30 2023
-1.00
-1.01
-0.81
Beat
19.6
Jun. 30 2023
-0.68
-1.30
-1.07
Beat
17.7​
Mar. 31 2023
-1.31
-1.84
0.40
Beat
121.7
Dec. 31 2022
-1.88
-8.00
Missed
-324.6

This summary was machine generated March 21 at 23:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)